Jeroen is a senior associate in NautaDutilh’s intellectual property group. He specialises in international technology-oriented matters, spanning a variety of fields including pharma, biotech and telecoms. His work encompasses litigation as well as regulatory work, for clients ranging from household companies to startups and spin-offs. He gained experience from working as a secondee with a major player in the Dutch pharmaceutical field in 2013. In 2017, he worked at the firm’s New York office. Jeroen also regularly advises on licensing and technology-related M&A and was part of the team working on a number of high profile life sciences transactions such as Dezima Pharma B.V.’s USD 1.5 billion acquisition by Amgen Inc. as well as a number of biotech IPOs.
Jeroen is an active member of the International Association for the Protection of Intellectual Property (AIPPI), the Dutch Society for Pharmaceutical Law (Vereniging voor Farma en Recht) and the International Trademark Association (INTA). Currently, he is the Dutch delegate of AIPPI's Biotechnology committee. Jeroen is a guest lecturer in patent law at the University of Groningen and he regularly publishes on intellectual property related topics. In 2019, he has received the Dutch AIPPI award for his publication on the transferability of patent priority rights, which is awarded each year by the AIPPI for best publication in the field of intellectual property or unfair competition law. He is a member of the Editorial Board of the EPLAW Patent Blog.
Jeroen obtained his master's degree in law (cum laude) from the University of Groningen in 2012 and joined NautaDutilh that same year.